An Open,Single-center,Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors
Latest Information Update: 06 Dec 2024
At a glance
- Drugs Cyclophosphamide (Primary) ; FIT 003 (Primary) ; Interleukin-2 (Primary) ; Serplulimab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Acronyms TAL-T
- Sponsors Guangzhou FineImmune Biotechnology
Most Recent Events
- 14 Mar 2024 New trial record